## Daniel M Witt

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4277683/daniel-m-witt-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,765 60 109 27 h-index g-index citations papers 5.6 4,578 113 5.24 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
109	Concordance of experienced-based maintenance warfarin dosing vs. algorithm-based dosing. <i>Thrombosis Update</i> , <b>2022</b> , 6, 100093	0.9	
108	Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study <i>American Heart Journal</i> , <b>2022</b> , 248, 42-42	4.9	0
107	Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 1	5.1	
106	Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management. <i>Thrombosis Update</i> , <b>2022</b> , 7, 100105	0.9	
105	A survey of current anticoagulation patient education practices and development. <i>Thrombosis Research</i> , <b>2021</b> , 208, 11-13	8.2	
104	Wearable sensors enable personalized predictions of clinical laboratory measurements. <i>Nature Medicine</i> , <b>2021</b> , 27, 1105-1112	50.5	30
103	A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism. <i>Thrombosis Research</i> , <b>2021</b> , 203, 190-195	8.2	3
102	Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 414-418	5.1	
101	Provider perceptions of extended venous thromboembolism prophylaxis for hospitalized medically ill patients. <i>Thrombosis Update</i> , <b>2021</b> , 2, 100034	0.9	
100	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , <b>2021</b> , 5, 4721-4726	7.8	3
99	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 138, 115-127	5.7	1
98	A risk-stratified approach to venous thromboembolism prophylaxis with aspirin or warfarin following total hip and knee arthroplasty: A cohort study. <i>Thrombosis Research</i> , <b>2021</b> , 206, 120-127	8.2	
97	Development of a brief screening instrument for emotional distress associated with thromboembolism. <i>Thrombosis Update</i> , <b>2020</b> , 1, 100015	0.9	O
96	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , <b>2020</b> , 4, 2351-2365	7.8	16
95	Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study. <i>Thrombosis Research</i> , <b>2020</b> , 189, 112-118	8.2	7
94	The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 739-745	5.1	O
93	Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1133-1140	15.4	O

## (2019-2020)

92	Fostering PharmD Skills Related to Research and Quality Improvement Through Mentored Projects. <i>American Journal of Pharmaceutical Education</i> , <b>2020</b> , 84, ajpe7940	2.5	2
91	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , <b>2020</b> , 4, 4693-4738	7.8	187
90	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , <b>2020</b> , 4, 1539-1553	7.8	6
89	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. <i>Blood Advances</i> , <b>2020</b> , 4, 500-513	7.8	5
88	Associations between anticoagulant treatment pathways and self-reported harms in patients recently diagnosed with venous thromboembolism. <i>Thrombosis Research</i> , <b>2019</b> , 182, 95-100	8.2	
87	Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 1450-1457.e1	2.4	9
86	Understanding Factors Associated with Quality of Life in Patients with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1869-1876	7	4
85	Windows Into Human Health Through Wearables Data Analytics. <i>Current Opinion in Biomedical Engineering</i> , <b>2019</b> , 9, 28-46	4.4	58
84	Understanding patients ware barriers in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 35-41	5.1	2
83	Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 506-510	5.1	3
82	Outcomes associated with a change in clinical practice to alleviate emotional harm related to venous thromboembolism. <i>Thrombosis Research</i> , <b>2019</b> , 180, 29-31	8.2	1
81	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. <i>European Journal of Epidemiology</i> , <b>2019</b> , 34, 173-190	12.1	35
80	Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. <i>Blood Advances</i> , <b>2019</b> , 3, 789-796	7.8	15
79	Accuracy of ICD-10 codes for identifying hospitalizations for acute anticoagulation therapy-related bleeding events. <i>Thrombosis Research</i> , <b>2019</b> , 181, 71-76	8.2	13
78	Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 181-186	5.1	10
77	Assessing patient preferences for switching from warfarin to direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 596-602	5.1	3
76	A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism. <i>Pharmacy Practice</i> , <b>2019</b> , 17, 1539	1.8	2
75	ProvidersWtilization and perceptions of warfarin dosing algorithms. <i>Thrombosis Research</i> , <b>2019</b> , 183, 4-12	8.2	2

74	Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. <i>Pharmacy Practice</i> , <b>2019</b> , 17, 1709	1.8	3
73	Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , <b>2019</b> , 3, 158-167	7.8	71
72	A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. <i>Blood Advances</i> , <b>2019</b> , 3, 1638-1646	7.8	9
71	Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. <i>Pharmacy Practice</i> , <b>2019</b> , 17, 1709	1.8	6
70	Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. <i>Thrombosis Research</i> , <b>2018</b> , 163, 54-59	8.2	8
69	Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 172-178	3.3	7
68	Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model. <i>Thrombosis Research</i> , <b>2018</b> , 172, 181-187	8.2	12
67	American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Advances</i> , <b>2018</b> , 2, 3257-3291	7.8	199
66	Survey of potential receptivity to robotic-assisted exercise coaching in a diverse sample of smokers and nonsmokers. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197090	3.7	5
65	Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 261-269	5.3	23
64	Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. <i>Medical Care</i> , <b>2017</b> , 55, e137-e143	3.1	71
63	Results of a Regional Effort to Improve Warfarin Management. <i>Annals of Pharmacotherapy</i> , <b>2017</b> , 51, 373-379	2.9	7
62	Assessment of the coding accuracy of warfarin-related bleeding events. <i>Thrombosis Research</i> , <b>2017</b> , 159, 86-90	8.2	20
61	Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1311-1321	15.1	99
60	Stroke diagnosis associated with thrombophilia testing overutilization. <i>Thrombosis Research</i> , <b>2017</b> , 157, 139-141	8.2	7
59	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2017</b> , 160, 97-104	8.2	11
58	Patterns and Appropriateness of Thrombophilia Testing in an Academic Medical Center. <i>Journal of Hospital Medicine</i> , <b>2017</b> , 12, 705-709	2.7	14
57	Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. <i>Thrombosis Research</i> , <b>2016</b> , 137, 97-102	8.2	4

## (2013-2016)

56	Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 187-205	5.1	70
55	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <i>European Journal of Epidemiology</i> , <b>2016</b> , 31, 541-61	12.1	15
54	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 671-81	5.3	5
53	Outcomes in adults with acute pulmonary embolism who are discharged from emergency departments: the Cardiovascular Research Network Venous Thromboembolism study. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1060-2	11.5	17
52	Clinical outcomes and adherence to guideline recommendations during the initial treatment of acute venous thromboembolism. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 869-75	2.9	5
51	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. <i>Thrombosis Research</i> , <b>2015</b> , 136, 1040-4	8.2	23
50	Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 819-25	7	56
49	Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 524-31	5.8	9
48	An Education Program for Patient Self-Management of Warfarin <b>2015</b> , 19, 33-8		7
47	Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1163-8	11.5	70
46	Thrombophilia testing patterns amongst patients with acute venous thromboembolism. <i>Thrombosis Research</i> , <b>2015</b> , 136, 1160-4	8.2	12
45	Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. <i>BMJ Open</i> , <b>2015</b> , 5, e009518	3	6
44	Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty. <i>Thrombosis Research</i> , <b>2015</b> , 135, 267-71	8.2	4
43	Impact of a clinical pharmacy research team on pharmacy resident research. <i>American Journal of Health-System Pharmacy</i> , <b>2015</b> , 72, 309-16	2.2	12
42	Warfarin interactions with antibiotics in the ambulatory care setting. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 409-16	11.5	35
41	Nonadherence with INR monitoring and anticoagulant complications. <i>Thrombosis Research</i> , <b>2013</b> , 132, e124-30	8.2	24
40	Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. <i>Thrombosis Research</i> , <b>2013</b> , 132, 770-5	8.2	30
39	Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplasty. <i>Thrombosis Research</i> , <b>2013</b> , 131, 390-5	8.2	6

38	Evolution, current structure, and role of a primary care clinical pharmacy service in an integrated managed care organization. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 124-31	2.9	13
37	Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1184-90	5.8	7
36	Challenges to publishing pharmacy resident research projects from the perspectives of residency program directors and residents. <i>Pharmacy Practice</i> , <b>2013</b> , 11, 166-72	1.8	33
35	Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting. <i>Blood</i> , <b>2013</b> , 122, 1143-1143	2.2	0
34	Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring. <i>Pharmacotherapy</i> , <b>2012</b> , 32, 1078-84	5.8	6
33	A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy. <i>Thrombosis Research</i> , <b>2012</b> , 130, 152-6	8.2	5
32	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 1484-91		157
31	Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e152S-e184S	5.3	920
30	Publication rates of abstracts presented by pharmacy residents at the Western States Conference. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 59-62	2.2	51
29	Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. <i>Oncologist</i> , <b>2012</b> , 17, 419-27	5.7	42
28	Approaches to optimal dosing of vitamin K antagonists. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 667-72	5.3	13
27	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 429-38	7	273
26	Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 472-7	5.1	8
25	Evaluation of venous thromboembolism risk following hospitalization. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 32, 32-9	5.1	8
24	Quality measures and benchmarking for warfarin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 242-8	5.1	6
23	Optimizing use of current anticoagulants. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, 717-26, viii	3.1	9
22	Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy. <i>Thrombosis Research</i> , <b>2010</b> , 125, 402-5	8.2	3
21	Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 29, 316-21	5.1	10

20	A descriptive evaluation of unfractionated heparin use during pregnancy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 267-73	5.1	19
19	A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services. Journal of Thrombosis and Thrombolysis, <b>2009</b> , 27, 334-9	5.1	6
18	Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. <i>Pharmacotherapy</i> , <b>2008</b> , 28, 960-7	5.8	37
17	The Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service as a model of modern anticoagulant care. <i>Thrombosis Research</i> , <b>2008</b> , 123 Suppl 1, S36-41	8.2	12
16	Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 979-88	2.9	75
15	Outcomes associated with combined antiplatelet and anticoagulant therapy. <i>Chest</i> , <b>2008</b> , 133, 948-54	5.3	60
14	Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. <i>Chest</i> , <b>2007</b> , 131, 1500-7	5.3	30
13	Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation. <i>Chest</i> , <b>2007</b> , 131, 816-822	5.3	13
12	An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2005</b> , 19, 209-12	5.1	5
11	Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. <i>Chest</i> , <b>2005</b> , 127, 1515-22	5.3	278
10	Use of Low Dose Oral Vitamin K in the Treatment of Patients with INR Values of More Than 10.0 <i>Blood</i> , <b>2005</b> , 106, 547-547	2.2	
9	ASHP Therapeutic Position Statement on the Use of Low-Molecular-Weight Heparins for Adult Outpatient Treatment of Acute Deep-Vein Thrombosis. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 1950-5	2.2	13
8	Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes. <i>Chest</i> , <b>2004</b> , 126, 1262-6	5.3	51
7	A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2003</b> , 15, 113-8	5.1	24
6	Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 360-8	5.8	15
5	Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 1159-66	5.8	60
4	Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. <i>Archives of Internal Medicine</i> , <b>2000</b> , 160, 2926-32		68
3	Controversies surrounding estrogen use in postmenopausal women. <i>Annals of Pharmacotherapy</i> , <b>1997</b> , 31, 745-55	2.9	25

Lack of interaction between glipizide and co-trimoxazole. *Journal of Clinical Pharmacology*, **1994**, 34, 997-1002

2.9 1

Amiodarone-clonazepam interaction. Annals of Pharmacotherapy, 1993, 27, 1463-4

2.9 8